NCT01702363 - Long-term Safety Study for GSK573719 in Japanese | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK573719

GSK573719 inhalation powder inhaled orally once daily for 52 weeks.

Trial Locations (20)

811-1347

GSK Investigational Site, Fukuoka

371-0048

GSK Investigational Site, Gunma

080-0805

GSK Investigational Site, Hokkaido

670-0849

GSK Investigational Site, Hyōgo

300-0053

GSK Investigational Site, Ibaraki

302-0022

GSK Investigational Site, Ibaraki

920-8610

GSK Investigational Site, Ishikawa

239-0821

GSK Investigational Site, Kanagawa

601-1495

GSK Investigational Site, Kyoto

983-0824

GSK Investigational Site, Miyagi

391-0011

GSK Investigational Site, Nagano

530-0001

GSK Investigational Site, Osaka

589-0022

GSK Investigational Site, Osaka

870-0921

GSK Investigational Site, Ōita

876-0047

GSK Investigational Site, Ōita

436-0022

GSK Investigational Site, Shizuoka

103-0027

GSK Investigational Site, Tokyo

153-8934

GSK Investigational Site, Tokyo

192-0903

GSK Investigational Site, Tokyo

400-0031

GSK Investigational Site, Yamanashi